203519-36-2 Usage
Uses
Used in Pharmaceutical Research:
1-(4-Fluorobenzoyl)homopiperazine, 95% is used as a research compound for pharmaceutical applications due to its high purity level. It can be utilized in the development and synthesis of new drugs, particularly those targeting the central nervous system, as homopiperazine-based compounds have shown potential in this area.
Used in Chemical Synthesis:
1-(4-Fluorobenzoyl)homopiperazine, 95% is used as a starting material or intermediate in the synthesis of other organic compounds. Its unique structure and high purity make it a valuable component in the creation of various chemical products, including those with potential applications in the pharmaceutical, agrochemical, and materials science industries.
Used in Research and Development:
1-(4-Fluorobenzoyl)homopiperazine, 95% is used as a research tool in academic and industrial laboratories. Its high purity ensures that it can be employed in a wide range of experiments, including those focused on understanding the compound's chemical properties, reactivity, and potential applications in various fields.
Used in the Synthesis of Fluorinated Compounds:
1-(4-Fluorobenzoyl)homopiperazine, 95% is used as a precursor in the synthesis of fluorinated compounds. The presence of the fluorine atom in the 4-fluorobenzoyl group can impart unique properties to the resulting compounds, making them valuable in various applications, such as pharmaceuticals, agrochemicals, and materials with specific physical or chemical characteristics.
Check Digit Verification of cas no
The CAS Registry Mumber 203519-36-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,5,1 and 9 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 203519-36:
(8*2)+(7*0)+(6*3)+(5*5)+(4*1)+(3*9)+(2*3)+(1*6)=102
102 % 10 = 2
So 203519-36-2 is a valid CAS Registry Number.
203519-36-2Relevant academic research and scientific papers
Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists
Nitta, Aiko,Iura, Yosuke,Tomioka, Hiroki,Sato, Ippei,Morihira, Koichiro,Kubota, Hirokazu,Morokata, Tatsuaki,Takeuchi, Makoto,Ohta, Mitsuaki,Tsukamoto, Shin-Ichi,Imaoka, Takayuki,Takahashi, Toshiya
, p. 4951 - 4954 (2012/08/28)
The synthesis and structure-activity relationships of ureas as CCR3 antagonists are described. Optimization starting with lead compound 2 (IC 50 = 190 nM) derived from initial screening hit compound 1 (IC 50 = 600 nM) led to the iden
